Other languages Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Market Closed - OTC Markets Other stock markets 03:51:30 2024-05-28 pm EDT			5-day change	1st Jan Change
0.0591 ^USD	+0.17%		-1.99%	-15.69%

2023	Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-14
Sector Update: Health Care Stocks Steady Premarket Tuesday	23-07-18
Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket	23-07-18
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours	23-07-17
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301	23-07-17
Aridisâ€™ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDAâ€™s Qualified Infectious Diseases Product Designation	23-07-12
Aridis Pharmaceuticals' AR-301 Eligible for Consideration Under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs	23-06-20
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-08
Sector Update: Health Care Stocks Advancing Late Wednesday	23-05-31
Sector Update: Health Care	23-05-31
Top Midday Gainers	23-05-31
Aridis Pharmaceuticals, Inc. Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design	23-05-31
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-22
Aridis Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-05-21
Aridis Pharmaceuticals, Inc. Terminates License, Development and Commercialization Agreement with Serum	23-05-09
Aridis Pharmaceuticals, Inc. Announces the Resignation of Robert Ruffolo as Director	23-03-22
Aridis Pharmaceuticals Launching $2.28 Million Stock Offering; Shares Drop	23-03-14
Aridis Pharmaceuticals Says Phase 2a Cystic Fibrosis Trial Meets Targets; Shares Jump	23-03-13
Aridis Pharmaceuticals, Inc. Meets Primary and Secondary Endpoints in Phase 2A Study of AR-501 in Cystic Fibrosis Patients	23-03-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Other languages

Filters